ArticleTherapeutic advances in hematology2021

Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.

Roy Vitkon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.